by Sermonix Pharmaceuticals | Oct 2, 2023 | News
Results showed that younger age, non-visceral disease, prior tamoxifen and a longer total duration of AI use may be associated with higher baseline vaginal and/or vulvar symptomatology Findings were presented in a poster at The Menopause Society 2023 Annual Meeting...
by Sermonix Pharmaceuticals | Oct 2, 2023 | News
More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapy About half never or almost never felt sexual desire or interest in the previous month, particularly those whose sexual...
Recent Comments